Specialty pharmacies are among the most prized acquisition targets in healthcare, and the demand is easy to understand. Growth in specialty medications for complex and chronic conditions keeps expanding, and pharmacies with access to limited distribution drugs and strong payer relationships hold genuinely scarce, hard to replicate value. Private equity platforms and national pharmacy operators are competing to acquire specialty pharmacies, and that competition is driving premium multiples for businesses with clean accreditation, solid clinical programs, and diversified therapy mix. The accreditation, contracts, and clinical infrastructure that specialty work requires take years to build, so buyers would much rather purchase an established operation than start one from zero. That scarcity gives you real leverage. A stable patient base and strong manufacturer and payer relationships can carry your figure toward the top of the range. Many founders built these pharmacies through years of demanding regulatory and clinical work and are ready to capture that value. If retirement, easing your day to day role, or taking value off the table while valuations sit near their peak is on your mind, this is a strong time to sell.